Universal Beteiligungs und Servicegesellschaft mbH Buys New Position in Artivion, Inc. (NYSE:AORT)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH has invested $3.16 million in Artivion, Inc., acquiring approximately 128,637 shares, which constitutes around 0.30% of the company's stock.
• Artivion's earnings report showed a loss of $0.06 per share for the quarter, missing analyst expectations, but the company generated revenue of $98.98 million, exceeding analyst estimates.
• Analysts maintain a generally optimistic outlook, with a consensus target price of $32.40 and multiple research firms issuing "buy" or "strong buy" ratings on the stock.

Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Artivion, Inc. (NYSE:AORT - Free Report) in the first quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 128,637 shares of the company's stock, valued at approximately $3,162,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.30% of Artivion at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. Wasatch Advisors LP lifted its position in Artivion by 27.7% during the 4th quarter. Wasatch Advisors LP now owns 1,041,992 shares of the company's stock valued at $29,791,000 after acquiring an additional 226,160 shares during the period. Next Century Growth Investors LLC lifted its position in Artivion by 29.7% during the 4th quarter. Next Century Growth Investors LLC now owns 492,653 shares of the company's stock valued at $14,085,000 after acquiring an additional 112,918 shares during the period. Northern Trust Corp increased its stake in Artivion by 10.0% during the 4th quarter. Northern Trust Corp now owns 463,250 shares of the company's stock valued at $13,244,000 after purchasing an additional 42,170 shares in the last quarter. Oberweis Asset Management Inc. increased its stake in Artivion by 10.8% during the 4th quarter. Oberweis Asset Management Inc. now owns 312,900 shares of the company's stock valued at $8,946,000 after purchasing an additional 30,500 shares in the last quarter. Finally, Peregrine Capital Management LLC bought a new stake in Artivion during the 1st quarter valued at about $7,650,000. 86.37% of the stock is owned by hedge funds and other institutional investors.

Artivion Stock Performance

Shares of AORT stock remained flat at $30.91 during trading hours on Friday. 64,730 shares of the stock were exchanged, compared to its average volume of 418,331. The business has a 50 day moving average of $30.27 and a two-hundred day moving average of $27.90. Artivion, Inc. has a 52-week low of $21.97 and a 52-week high of $32.94. The firm has a market capitalization of $1.32 billion, a price-to-earnings ratio of -61.82 and a beta of 1.62. The company has a current ratio of 5.53, a quick ratio of 3.95 and a debt-to-equity ratio of 1.08.

Artivion (NYSE:AORT - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported $0.06 EPS for the quarter, missing analysts' consensus estimates of $0.12 by ($0.06). Artivion had a positive return on equity of 3.63% and a negative net margin of 5.49%. The company had revenue of $98.98 million during the quarter, compared to the consensus estimate of $94.81 million. Equities research analysts forecast that Artivion, Inc. will post 0.37 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on AORT shares. JMP Securities restated a "market outperform" rating and set a $33.00 price objective on shares of Artivion in a research note on Tuesday, May 6th. Needham & Company LLC restated a "buy" rating and set a $32.00 price objective on shares of Artivion in a research note on Tuesday, May 6th. Canaccord Genuity Group started coverage on shares of Artivion in a research note on Tuesday, June 17th. They set a "buy" rating and a $35.00 price objective for the company. Finally, Citizens Jmp upgraded shares of Artivion to a "strong-buy" rating in a research note on Tuesday, May 6th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $32.40.

Insider Transactions at Artivion

In other news, Director Anthony B. Semedo sold 2,600 shares of Artivion stock in a transaction that occurred on Friday, May 23rd. The shares were sold at an average price of $28.47, for a total value of $74,022.00. Following the completion of the sale, the director directly owned 33,059 shares in the company, valued at $941,189.73. The trade was a 7.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Marshall S. Stanton sold 15,000 shares of Artivion stock in a transaction that occurred on Tuesday, June 17th. The stock was sold at an average price of $29.50, for a total transaction of $442,500.00. Following the completion of the sale, the senior vice president owned 64,200 shares of the company's stock, valued at $1,893,900. This represents a 18.94% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 72,954 shares of company stock worth $2,108,525 over the last three months. 7.60% of the stock is currently owned by company insiders.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.